Back in early January, Bristol-Myers Squibb Co. (BMY) made an offer to acquire Celgene Corp. (CELG).
Several S.A. authors contributed thoughtful commentaries reflecting upon the April 12 shareholder voting outcome. If affirmative, the voting will clear the way for a third-quarter closing.
In this article, I'll weigh in, too: sharing an indicator I believe is a useful gauge to help cut through the market chatter.
Deal Basics And A Few Clarifications
Before checking the arb spread continuum, the highlights of the potential transaction are found below.
For reference, the Bristol-Myers press